Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
HBIO Harvard Bioscience Inc
- Stocks
- Healthcare
- NASDAQ: HBIO
Price (delayed)
$0.4636
Market cap
$20.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.31
Enterprise value
$58.14M
Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its customers range from renowned
Highlights
The equity has dropped by 78% year-on-year and by 77% since the previous quarter
HBIO's quick ratio has shrunk by 55% YoY and by 2.9% QoQ
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.harvardbioscience.com
Key stats
What are the main financial stats of HBIO
Market
Valuations
Earnings
Shares outstanding
44.21M
Market cap
$20.5M
Enterprise value
$58.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.38
Price to sales (P/S)
0.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.64
Revenue
$91.4M
Gross profit
$52.18M
Operating income
-$53.6M
Net income
-$58.05M
EBIT
-$54.72M
EBITDA
-$47.68M
Free cash flow
-$203,000
Per share
Balance sheet
Liquidity
EPS
-$1.31
EPS diluted
-$1.31
Free cash flow per share
$0
Book value per share
$0.34
Revenue per share
$2.07
TBVPS
$1.38
Total assets
$79.8M
Total liabilities
$64.97M
Debt
$43.19M
Equity
$14.84M
Working capital
-$10.7M
Debt to equity
2.91
Current ratio
0.81
Quick ratio
0.34
Net debt/EBITDA
-0.79
Margins
Efficiency
Dividend
EBITDA margin
-52.2%
Gross margin
57.1%
Net margin
-63.5%
Operating margin
-58.6%
Return on assets
-49.8%
Return on equity
-110.2%
Return on invested capital
-92.2%
Return on capital employed
-226.1%
Return on sales
-59.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HBIO stock price
How has the Harvard Bioscience stock price performed over time
Intraday
-9.44%
1 week
-12.81%
1 month
24.19%
1 year
-84.01%
YTD
-78.03%
QTD
-18.09%
Financial performance
How have Harvard Bioscience's revenue and profit performed over time
Revenue
$91.4M
Gross profit
$52.18M
Operating income
-$53.6M
Net income
-$58.05M
Gross margin
57.1%
Net margin
-63.5%
The gross profit has declined by 17% year-on-year and by 4.7% since the previous quarter
Harvard Bioscience's revenue has decreased by 14% YoY and by 2.9% from the previous quarter
HBIO's gross margin is down by 2.4% YoY
Price vs fundamentals
How does HBIO's price correlate with its fundamentals
Growth
What is Harvard Bioscience's growth rate over time
Valuation
What is Harvard Bioscience stock price valuation
P/E
N/A
P/B
1.38
P/S
0.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.64
The equity has dropped by 78% year-on-year and by 77% since the previous quarter
HBIO's price to book (P/B) is 43% less than its 5-year quarterly average of 2.4 and 19% less than its last 4 quarters average of 1.7
The stock's price to sales (P/S) is 86% less than its 5-year quarterly average of 1.6 and 76% less than its last 4 quarters average of 0.9
Harvard Bioscience's revenue has decreased by 14% YoY and by 2.9% from the previous quarter
Efficiency
How efficient is Harvard Bioscience business performance
Dividends
What is HBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HBIO.
Financial health
How did Harvard Bioscience financials performed over time
The total assets is 23% more than the total liabilities
HBIO's current ratio has dropped by 57% year-on-year
HBIO's quick ratio has shrunk by 55% YoY and by 2.9% QoQ
Harvard Bioscience's debt is 191% more than its equity
The equity has dropped by 78% year-on-year and by 77% since the previous quarter
Harvard Bioscience's debt has increased by 4.4% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.